{"id":6732,"date":"2024-04-19T09:28:47","date_gmt":"2024-04-19T09:28:47","guid":{"rendered":"https:\/\/lupus.treefrog.dev\/lanifrolumab-dastrazeneca-a-demontre-une-reduction-precoce-et-durable-de-lactivite-de-la-maladie-chez-les-patients-atteints-de-led-dans-lessai-clinique-de-phase-iii\/"},"modified":"2024-05-06T15:38:59","modified_gmt":"2024-05-06T15:38:59","slug":"lanifrolumab-dastrazeneca-a-demontre-une-reduction-precoce-et-durable-de-lactivite-de-la-maladie-chez-les-patients-atteints-de-led-dans-lessai-clinique-de-phase-iii","status":"publish","type":"post","link":"https:\/\/www.lupuscanada.org\/fr\/lanifrolumab-dastrazeneca-a-demontre-une-reduction-precoce-et-durable-de-lactivite-de-la-maladie-chez-les-patients-atteints-de-led-dans-lessai-clinique-de-phase-iii\/","title":{"rendered":"L\u2019anifrolumab d\u2019AstraZeneca a d\u00e9montr\u00e9 une r\u00e9duction pr\u00e9coce et durable de l\u2019activit\u00e9 de la maladie chez les patients atteints de LED dans l\u2019essai clinique de phase III Tulip"},"content":{"rendered":"\n<p>L\u2019essai de phase III Tulip sur l\u2019anifrolumab (un anticorps monoclonal qui bloque les interf\u00e9rons de type 1) a \u00e9valu\u00e9 l\u2019efficacit\u00e9 et l\u2019innocuit\u00e9 de l\u2019anifrolumab dans le LED \u00e0 auto-anticorps positifs qui re\u00e7oivent le traitement standard. En plus d\u2019atteindre le crit\u00e8re d\u2019\u00e9valuation principal, l\u2019essai Tulip 2 fournit des r\u00e9sultats encourageants quant \u00e0 l\u2019efficacit\u00e9 de l\u2019anifrolumab dans le LED mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re.<\/p>\n\n<p><strong>Source : <\/strong><a href=\"https:\/\/www.astrazeneca.com\/media-centre\/medical-releases\/anifrolumab-showed-early-and-sustained-treatment-benefit-for-patients-with-systemic-lupus-erythematosus-in-the-tulip-clinical-trial-programme.html\" target=\"_blank\" rel=\"noreferrer noopener\">\n  <strong>https:\/\/www.astrazeneca.com\/media-centre\/medical-releases\/anifrolumab-showed-early-and-sustained-treatment-benefit-for-patients-with-systemic-lupus-erythematosus-in-the-tulip-clinical-trial-programme.html<\/strong>\n<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019essai de phase III Tulip sur l\u2019anifrolumab (un anticorps monoclonal qui bloque les interf\u00e9rons de type 1) a \u00e9valu\u00e9 l\u2019efficacit\u00e9 et l\u2019innocuit\u00e9 de l\u2019anifrolumab dans le LED \u00e0 auto-anticorps positifs qui re\u00e7oivent le traitement standard. En plus d\u2019atteindre le crit\u00e8re d\u2019\u00e9valuation principal, l\u2019essai Tulip 2 fournit des r\u00e9sultats encourageants quant \u00e0 l\u2019efficacit\u00e9 de l\u2019anifrolumab dans [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[92],"tags":[],"topic":[113,115],"audience":[123,122,125,124],"class_list":["post-6732","post","type-post","status-publish","format-standard","hentry","category-article-fr","topic-nouvelles-et-evenements","topic-recherche-et-essais-cliniques","audience-j-ai-le-lupus","audience-j-ai-recemment-recu-un-diagnostic","audience-professionnel-de-la-sante","audience-une-personne-a-qui-je-tiens-a-le-lupus"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/6732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/comments?post=6732"}],"version-history":[{"count":0,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/6732\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/media?parent=6732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/categories?post=6732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/tags?post=6732"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/topic?post=6732"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/audience?post=6732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}